SCHEMBL8533100

SCHEMBL8533100

CC(C)(F)CN1CCC(Oc2ccc(-n3ccc4cc(C(=O)NCCO)ccc43)nc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.40
FLT3 P36888 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ROCK1 Q13464 1/20 0.38
FAAH O00519 1/20 0.37
EPHX2 P34913 1/20 0.37
P2RX3 P56373 1/20 0.37
P2RX2 Q9UBL9 1/20 0.37
HPGDS O60760 3/20 0.37
CCR3 P51677 1/20 0.37
IDH1 O75874 2/20 0.37
FGFR1 P11362 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
NPC1 O15118 1/20 0.36
ACACB O00763 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15253109 0.86 CHEK2 (0.42) L3MBTL1
SCHEMBL8533555 0.86 ROCK1 (0.42) POLBRAB9AL3MBTL1ROCK1NPC1
SCHEMBL15253330 0.85 HRH3 (0.45) POLBHRH3
SCHEMBL15253298 0.85 HRH3 (0.44) POLBHRH3
SCHEMBL15253243 0.85 GPR119 (0.42) POLBRAB9AL3MBTL1ROCK1NPC1
SCHEMBL9262615 0.84 KDM1A (0.42) ROCK1FAAHEPHX2GSK3BDYRK1A
SCHEMBL8530737 0.84 PIK3CD (0.41) L3MBTL1
SCHEMBL8535909 0.83 GPR119 (0.52) RAB9AL3MBTL1ACACB
SCHEMBL15253108 0.83 ROCK1 (0.38) RAB9AL3MBTL1ROCK1HPGDSIDH1
SCHEMBL8537358 0.83 ROCK1 (0.41) POLBRAB9AL3MBTL1ROCK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US claimed
EP-2643311-A1 BICYCLIC GPR119 MODULATORS Lupin Limited (IN) 2013-10-02 EP claimed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US claimed
WO-2012069917-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2012-05-31 WO claimed
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US disclosed
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US disclosed
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US disclosed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US disclosed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US disclosed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US disclosed
WO-2012069917-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245000-A1 BICYCLIC GPR119 MODULATORS GPR119, GPR180, GPBAR1 CSF1R 490/4885FLT3 2543/4885POLB 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.